Soretolide: Laboratoires Biocodex

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Laboratoires Biocodex is developing soretolide (D-2916) as a potential treatment for epilepsy. It is currently in phase II trials. In animal models, soretolide shows an anticonvulsant profile similar to carbamazepine, being active in the maximal electroshock test and poorly active against pentylenetetrazole-induced seizures. The company is currently discussing future development plans for this drug.

Original languageEnglish
Pages (from-to)824-827
Number of pages4
JournalCurrent Opinion in Investigational Drugs
Volume2
Issue number6
Publication statusPublished - 2001

Fingerprint

Electroshock
Pentylenetetrazole
Carbamazepine
Anticonvulsants
Epilepsy
Seizures
Animal Models
Pharmaceutical Preparations
soretolide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Soretolide : Laboratoires Biocodex. / Fatope, M. O.

In: Current Opinion in Investigational Drugs, Vol. 2, No. 6, 2001, p. 824-827.

Research output: Contribution to journalArticle

@article{549b824f63014031b13f9fb8e4ceda8d,
title = "Soretolide: Laboratoires Biocodex",
abstract = "Laboratoires Biocodex is developing soretolide (D-2916) as a potential treatment for epilepsy. It is currently in phase II trials. In animal models, soretolide shows an anticonvulsant profile similar to carbamazepine, being active in the maximal electroshock test and poorly active against pentylenetetrazole-induced seizures. The company is currently discussing future development plans for this drug.",
author = "Fatope, {M. O.}",
year = "2001",
language = "English",
volume = "2",
pages = "824--827",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Soretolide

T2 - Laboratoires Biocodex

AU - Fatope, M. O.

PY - 2001

Y1 - 2001

N2 - Laboratoires Biocodex is developing soretolide (D-2916) as a potential treatment for epilepsy. It is currently in phase II trials. In animal models, soretolide shows an anticonvulsant profile similar to carbamazepine, being active in the maximal electroshock test and poorly active against pentylenetetrazole-induced seizures. The company is currently discussing future development plans for this drug.

AB - Laboratoires Biocodex is developing soretolide (D-2916) as a potential treatment for epilepsy. It is currently in phase II trials. In animal models, soretolide shows an anticonvulsant profile similar to carbamazepine, being active in the maximal electroshock test and poorly active against pentylenetetrazole-induced seizures. The company is currently discussing future development plans for this drug.

UR - http://www.scopus.com/inward/record.url?scp=0034789667&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034789667&partnerID=8YFLogxK

M3 - Article

C2 - 11572664

AN - SCOPUS:0034789667

VL - 2

SP - 824

EP - 827

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -